CTH120
Fragile X Syndrome (FXS)
Phase 2 (Preparation)Active
Key Facts
Indication
Fragile X Syndrome (FXS)
Phase
Phase 2 (Preparation)
Status
Active
Company
About Connecta Therapeutics
Connecta Therapeutics is a private, pre-revenue biotech founded in 2019, advancing a novel neuroplasticity modulation platform. Its lead asset, CTH120, is a first-in-class TrkB modulator that has completed a positive Phase I trial and is preparing for Phase II development in pediatric Fragile X Syndrome (FXS), supported by a €2.5M EIC Accelerator grant. The company operates as an R&D-intensive organization aiming to develop disease-modifying therapies for CNS disorders where current treatments are limited or non-existent.
View full company profileTherapeutic Areas
Other Fragile X Syndrome (FXS) Drugs
| Drug | Company | Phase |
|---|---|---|
| FMR1 Program | Quiver Bioscience | Discovery |
| Fragile X Syndrome Candidate | Shionogi | Phase 3 |